NCT04096417View on ClinicalTrials.gov

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

May 13, 2022

Study Completion Date

December 1, 2025

Conditions
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene TranslocationFGFR2 Gene AmplificationFGFR2 Gene MutationFGFR2 Gene TranslocationFGFR3 Gene AmplificationFGFR3 Gene MutationFGFR3 Gene TranslocationMetastatic Colorectal CarcinomaStage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Unresectable Colorectal Carcinoma
Interventions
DRUG

Pemigatinib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (6)

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

37232

Vanderbilt University/Ingram Cancer Center, Nashville

53226

Aurora Cancer Care-Milwaukee West, Wauwatosa

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER